hero image

Biogen Announces Departure of Tony Kingsley

October 9, 2015 Corporate

John Cox to Lead Commercial Operations on Interim Basis


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) today announced that Tony Kingsley, executive vice president, Global Commercial Operations, will leave the company and a search has been initiated for a permanent replacement. In the interim his responsibilities will be assumed by John G. Cox, executive vice president, Pharmaceutical Operations & Technology.

“Tony has made significant contributions to Biogen,” said George A. Scangos, Ph.D., chief executive officer. “He led the successful introduction of five important new products and helped serve patients around the world with our life-transforming therapies. All of us wish Tony the best in his future endeavors.”

John Cox has served in his current position since June 2010. He joined Biogen in 2003 and has held several senior executive positions with us, including Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, and Vice President of Manufacturing and General Manager of Biogen’s operations in Research Triangle Park, North Carolina.

“We are pleased that John will lead our commercial operations on an interim basis,” Scangos continued. “His 12 years at Biogen and in-depth knowledge of our pharmaceutical and commercial operations give us great confidence that we will continue to execute on the commercial opportunities at-hand as we search for a permanent leader.”

Kingsley joined Biogen in January 2010 as Senior Vice President, U.S. Commercial Operations and has been in his current position since November 2011. During his tenure, Biogen introduced five new therapies, including successfully launching TECFIDERA® (dimethyl fumarate), the most-prescribed oral treatment for multiple sclerosis today. His leadership contributed to the company’s revenue growth of 108% during his tenure. Prior to his time at Biogen, Tony served as Senior Vice President and General Manager of the Gynecological Surgical Products business at Hologic, Inc., Division President, Diagnostic Products at Cytyc Corp., and was a Partner at McKinsey & Company.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com.



Media Contact:
Jason Glashow, +1 781-464-3260
Investor Contact:
Carlo Tanzi, Ph.D., +1 781-464-2442

February 13, 2024
Biogen Reports Fourth Quarter and Full Year 2023 Results
February 12, 2024
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients